Phase 3 trial in 1,402 participants with resected stage IIB-IV melanoma: adding vibostolimab to adjuvant pembrolizumab gave no benefit at the first interim analysis (recurrence-free survival HR 1.25, 95% CI 0.9-1.8) and was stopped for futility.
RCTn = 1,402
Dummer et al. Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study